November 9th 2022
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
November 2nd 2022
In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
October 26th 2022
Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
October 19th 2022
Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
October 12th 2022
Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
October 5th 2022
Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
September 28th 2022
Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
September 21st 2022
Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
September 8th 2022
Mark Yarchoan, MD, discusses the addition of durvalumab (Imfinzi) to gemcitabine and cisplatin in biliary tract cancer.
August 24th 2022
Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.
August 17th 2022
Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.
Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.